Shilpa Biologicals has entered into a 3-year DefInitive Agreement with Dr. Reddy’s Laboratories to produce Sputnik V
Under the agreement, Shilpa Biologicals will be responsible for manufacturing the COVID-19 vaccine, while Dr. Reddy’s is responsible for the distribution/marketing of the vaccine in its marketing territories.
Shilpa Biologicals Private Limited, wholly-owned subsidiary of Shilpa Medicare has joined hands with Dr. Reddy’s to manufacture Sputnik V COVID-19 vaccine in Inida. “Shilpa Biologicals Private Limited (SBPL), has entered into a 3 year DefInitive Agreement with Dr. Reddy’s Laboratories Limited (DRL) for production-supply of the Sputnik V vaccine from its integrated
biologics R&D cum manufacturing center at Dharwad, Karnataka,” the pharma copmany said in a regulatory filing.
“The targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses (50 million of Component 1 and 50 million of component 2), from the date of start of commercial production,” it further added.
The COVID-19 vaccine will be made at the company’s integrated biologics research and development cum manufacturing centre in Dharwad, Karnataka. Under the agreement, Shilpa Biologicals will be responsible for manufacturing the vaccine, while Dr. Reddy’s is responsible for the distribution/marketing of the vaccine in its marketing territories.
The companies are also exploring the option to manufacture Sputnik Light, a single dose version of the vaccine in the near future, the statement added.
Read all the Latest News, Breaking News and Coronavirus News here
Source: News18